- Home
- MIRM vs PRVA Comparison
MIRM vs PRVA Comparison
Compare MIRM & PRVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- PRVA
- Stock Information
- Founded
- MIRM 2018
- PRVA 2007
- Country
- MIRM United States
- PRVA United States
- Employees
- MIRM N/A
- PRVA N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- PRVA Retail: Computer Software & Peripheral Equipment
- Sector
- MIRM Health Care
- PRVA Technology
- Exchange
- MIRM Nasdaq
- PRVA Nasdaq
- Market Cap
- MIRM 2.5B
- PRVA 2.7B
- IPO Year
- MIRM 2019
- PRVA 2021
- Fundamental
- Price
- MIRM $48.39
- PRVA $22.58
- Analyst Decision
- MIRM Strong Buy
- PRVA Strong Buy
- Analyst Count
- MIRM 9
- PRVA 14
- Target Price
- MIRM $66.22
- PRVA $27.93
- AVG Volume (30 Days)
- MIRM 463.0K
- PRVA 1.0M
- Earning Date
- MIRM 08-06-2025
- PRVA 08-07-2025
- Dividend Yield
- MIRM N/A
- PRVA N/A
- EPS Growth
- MIRM N/A
- PRVA N/A
- EPS
- MIRM N/A
- PRVA 0.12
- Revenue
- MIRM $379,251,000.00
- PRVA $1,801,244,000.00
- Revenue This Year
- MIRM $35.83
- PRVA $90.63
- Revenue Next Year
- MIRM $16.83
- PRVA $10.51
- P/E Ratio
- MIRM N/A
- PRVA $191.74
- Revenue Growth
- MIRM 69.31
- PRVA 6.79
- 52 Week Low
- MIRM $33.45
- PRVA $16.47
- 52 Week High
- MIRM $54.23
- PRVA $26.09
- Technical
- Relative Strength Index (RSI)
- MIRM 50.61
- PRVA 51.69
- Support Level
- MIRM $49.39
- PRVA $21.55
- Resistance Level
- MIRM $51.93
- PRVA $23.11
- Average True Range (ATR)
- MIRM 1.52
- PRVA 0.69
- MACD
- MIRM -0.18
- PRVA 0.08
- Stochastic Oscillator
- MIRM 14.49
- PRVA 70.87
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About PRVA Privia Health Group Inc.
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.